Yingsheng Science (00209) issued an announcement. On April 16, 2024, the company and an independent third party (battle...
Zhitong Finance App News, Yingsheng Science (00209) announced that on April 16, 2024, the company signed a memorandum of understanding with an independent third party (strategic partner) on strategic cooperation (strategic cooperation) in the medical field. According to the memorandum of understanding, the two sides plan to establish a long-term strategic partnership to jointly develop business in the new medical aesthetic market, including entering the API market, with a view to achieving mutual benefit and common progress in technology in the medical field to meet the broader needs of human health.
The company will have the right to conduct due diligence on the medical aesthetic business of the strategic partner. Afterwards, the company will establish a subsidiary to carry out the above business and establish a business partnership with the strategic partner. The scope of cooperation includes, but is not limited to, the R&D, manufacture, sale and marketing of medical aesthetic-related drugs (including drugs that promote weight loss).
Strategic partners have accumulated several years of experience in the field of genetically recombinant peptides and protein drugs. According to the directors' knowledge, knowledge and belief after making all reasonable inquiries, the strategic partner and its ultimate beneficial owner are independent third parties to the company and its related persons, and are unrelated to the company and its related persons.
The Group is mainly engaged in the business of manufacturing and trading toys and growing and selling agricultural products, and is always looking for opportunities to develop high-growth businesses to maintain its competitiveness. The strategic cooperation will meet the Group's business development needs, help the Group diversify its business, and provide the Group with growth opportunities in the emerging medical aesthetic market in response to the high demand for related products. The Board believes that the strategic cooperation is in line with the Group's business strategy. It is expected that if the strategic cooperation is realized, it will enhance the Group's competitiveness and generate higher returns for the company's shareholders.